Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + azacitidine + cladribine for newly diagnosed AML in older, unfit, or young high-risk patients
ChiCTR2300074386Phase 2Recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, azacitidine and cladribine in acute myeloid leukemia (AML), sponsored by The First Hospital of Jilin University. Primary endpoints: Composite complete remission rate and Median remission time. Started Aug 2023; status: recruiting.
02
Drugs
venetoclaxazacitidinecladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2300074386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074386.